REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Bolt Biotherapeutics Inc. (BOLT) on Monday reported a loss of $15.9 million in its fourth quarter. The Redwood City, California-based ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based ...

Protalix BioTherapeutics Inc. earnings at a glance (GAAP) : -Earnings: $2.93 Mln. vs. $8.31 Mln. last year. -EPS: $0.04 vs. $0.09 last year. -Revenue: $53.40 Mln vs. $65.49 Mln last year.

March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported ...

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...

In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other best stocks to penny stocks that will skyrocket. On March 21, Jason D.

Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a conditionally active monoclonal antibody targeting VISTA.

Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease ...

Story March 4 - Atara Biotherapeutics: While the biotech navigates the fallout from the FDA’s move to halt trials of its allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate ...